A global standard for the testing of mycoplasma contamination has been developed
Biological medicinal products such as recombinant proteins, monoclonal antibodies, and many vaccines are produced in cell cultures. Staff members of the Paul-Ehrlich-Institut have taken the lead in developing, on behalf of the WHO, the first internationally recognized reference preparation for tests detecting mycoplasma contamination in cell cultures.
Identification of a molecule that recognizes HIV in immune cells
In collaboration with colleagues from California and New York, researchers of the Paul-Ehrlich-Institut have identified a cytosolic receptor which enables cells of the immune system to recognize HIV and to trigger an immune response. The findings of the researchers may be a useful tool for creating an effective endogenous immune response against HIV and helpful to boost vaccine responses.
Annual Report 2013/14 of the Paul-Ehrlich-Institut published
Regulation of biomedicines, research and international key position: these are the key themes of the Annual Report 2013/14 of the Paul-Ehrlich-Institut (PEI). Its unique role as both a research institute and a medicines agency makes the PEI a major player in the development, benefit-risk analysis and assessment of vaccines and biomedicines and positions it as a strong partner in the network of European and international institutions of the health care system.